Abaloparatide Effective In Ignored Population: Men With Osteoporosis

However, a new data shows that the anabolic osteoporosis treatment abaloparatideworks in men as well as women,. Findings are from a randomized, double-blind, placebo-controlled, phase 3 study that was presented at the American Association of Clinical Endocrinology (AACE) Annual Meeting 2022. Abaloparatide, a subcutaneously administered parathyroid-hormone-related protein (PTHrP) analog, resulted in significant increases in bone mineral density by 12 months at the lumbar spine, total hip, and femoral neck compared with placebo in men with osteoporosis, with no significant adverse effects.

The approval of abaloparatide in women was based on the phase 3, 18-week ACTIVE trial of more than 2000 high-risk women, in whom abaloparatide was associated with an 86% reduction in vertebral fracture incidence compared with placebo, and also significantly greater reductions in nonvertebral fractures.

Hence, it was observed that osteoporosis is underdiagnosed in men and the Abaloparatide is another option for this group of ignored population.